Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-27T03:22:26.856Z Has data issue: false hasContentIssue false
  • English
  • Français

Prolonged prostaglandin-E2-associated periosteal reaction and elevated C-reactive protein levels

Published online by Cambridge University Press:  29 November 2017

Maria I. Duggan ,
Andrew T. MacLaren  and
Dhullipala Anand
Maria I. Duggan
Affiliation:
Department of Neonatal Medicine, Royal Hospital for Children, Glasgow, United Kingdom
Andrew T. MacLaren*
Affiliation:
Department of Neonatal Medicine, Royal Hospital for Children, Glasgow, United Kingdom
Dhullipala Anand
Affiliation:
Department of Neonatal Medicine, Royal Hospital for Children, Glasgow, United Kingdom
*
Correspondence to: Dr A. T. MacLaren, MBChB, BSc (Hons), MRCPCH, Department of Neonatal Medicine, Royal Hospital for Children, 4 Victoria Place, Barrhead, Glasgow, United Kingdom. Tel: +44 7828832420; Fax: +441412115796; E-mail: Andrew.maclaren@nhs.net
Get access Rights & Permissions [Opens in a new window]

Abstract

This is a case review of two infants who received a prolonged course of prostaglandin-E2 therapy for congenital cardiac lesions while awaiting corrective surgery. These cases highlight an association between prolonged prostaglandin-E2 therapy with periosteal reactions and elevated C-reactive protein levels. Failure to recognise this association may lead to multiple courses of antibiotics for presumed sepsis and further prolongation of prostaglandin-E2 therapy.

Keywords

Neonatal medicineneonatal cardiologyprostaglandin-E2CHD
Type
Brief Report
Information
Cardiology in the Young , Volume 28 , Issue 3 , March 2018 , pp. 482 - 484
Check for updates
Copyright
© Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Olley, PM, Coceani, F, Bodach, E. E-type prostaglandins. A new emergency therapy for certain cyanotic congenital heart malformations. Circulation 1976; 53: 728.Google Scholar
2. Freed, MD, Heymann, MA, Lewis, AB, Roehl, SL, Kensey, RC. Prostaglandin-E1 in infants with ductus arteriosus-dependent congenital heart disease. Circulation 1981; 64: 899.Google Scholar
3. Lucron, H, Chipaux, M, Bosser, G, et al. Complications of prostaglandin-E1 treatment of congenital heart disease in paediatric medical intensive care. Arch Mal Coeur Vaiss 2005; 98: 524–530.Google ScholarPubMed
4. Ueda, K, Saito, A, Nakano, H, et al. Cortical hyperostosis following long-term administration of prostaglandin E1 in infants with cyanotic congenital heart disease. J Pediatr 1980; 97: 834.Google Scholar
5. Sone, K, Tashiro, M, Fujinaga, T, et al. Long-term low-dose prostaglandin-E1 administration. J Pediatr 1980; 97: 866.Google Scholar
6. Boyce, BF, Aufdemorte, TB, Garrett, IR, Yates, AJ, Mundy, GR. Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 1989; 125: 1142–1150.Google Scholar
7. Tai, TC, Adamson, SL. Developmental changes in respiratory, febrile, and cardiovascular responses to PGE2 in newborn lambs. Am J Physiol Regul Integr Comp Physiol 2000; 278: 1460–1473.Google Scholar
8. Hinson, RM, Williams, JA, Shacter, E. Elevated interleukin-6 is induced by prostaglandin-E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci USA 1996; 93: 4885–4890.Google Scholar
9. Inoue, H, et al. Regulation by prostaglandin-E2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br J Pharmacol 2002; 136: 287–295.Google Scholar
10. Schmidt-Arras, D, Rose-John, S. Interleukin-6 pathway in the liver: from physiopathology to therapy. J Hepatol 2016; 64: 1403–1415.Google Scholar
11. Pepys, MB, Hirschfield, GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805–1812.Google Scholar